CN104761636A - 一种HLA-A33限制性eEF2表位多肽及其应用 - Google Patents
一种HLA-A33限制性eEF2表位多肽及其应用 Download PDFInfo
- Publication number
- CN104761636A CN104761636A CN201510173097.0A CN201510173097A CN104761636A CN 104761636 A CN104761636 A CN 104761636A CN 201510173097 A CN201510173097 A CN 201510173097A CN 104761636 A CN104761636 A CN 104761636A
- Authority
- CN
- China
- Prior art keywords
- eef2
- cell
- hla
- epitope polypeptide
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510173097.0A CN104761636B (zh) | 2015-04-14 | 2015-04-14 | 一种HLA-A33限制性eEF2表位多肽及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510173097.0A CN104761636B (zh) | 2015-04-14 | 2015-04-14 | 一种HLA-A33限制性eEF2表位多肽及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104761636A true CN104761636A (zh) | 2015-07-08 |
CN104761636B CN104761636B (zh) | 2018-04-27 |
Family
ID=53643768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510173097.0A Expired - Fee Related CN104761636B (zh) | 2015-04-14 | 2015-04-14 | 一种HLA-A33限制性eEF2表位多肽及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104761636B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105753978A (zh) * | 2016-03-14 | 2016-07-13 | 中国人民解放军第二军医大学 | 一种hla-a11限制性癌胚抗原来源的表位肽及用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102250208A (zh) * | 2010-05-18 | 2011-11-23 | 中国人民解放军第二军医大学 | 一种新的hla-a2限制性表位多肽及其应用 |
CN102348796A (zh) * | 2009-01-08 | 2012-02-08 | 株式会社癌免疫研究所 | 新型癌抗原eEF2 |
-
2015
- 2015-04-14 CN CN201510173097.0A patent/CN104761636B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102348796A (zh) * | 2009-01-08 | 2012-02-08 | 株式会社癌免疫研究所 | 新型癌抗原eEF2 |
CN102250208A (zh) * | 2010-05-18 | 2011-11-23 | 中国人民解放军第二军医大学 | 一种新的hla-a2限制性表位多肽及其应用 |
Non-Patent Citations (1)
Title |
---|
MARTINA KORFEI等: "Comparative Proteomic Analysis of Lung Tissue from Patients with Idiopathic Pulmonary Fibrosis (IPF) and Lung Transplant Donor Lungs", 《J. PROTEOME RES.》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105753978A (zh) * | 2016-03-14 | 2016-07-13 | 中国人民解放军第二军医大学 | 一种hla-a11限制性癌胚抗原来源的表位肽及用途 |
CN105753978B (zh) * | 2016-03-14 | 2020-02-07 | 中国人民解放军第二军医大学 | 一种hla-a11限制性癌胚抗原来源的表位肽及用途 |
Also Published As
Publication number | Publication date |
---|---|
CN104761636B (zh) | 2018-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101139392B (zh) | Kdr肽和包括该肽的疫苗 | |
US9238064B2 (en) | Allogeneic cancer cell-based immunotherapy | |
ES2373055T3 (es) | Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno. | |
TWI311586B (en) | Method of extended culture for antigen-specific cytotoxic t lumphocytes | |
CN107488235A (zh) | 一种新的增强型抗原联合多肽诱导肝癌特异性ctl细胞的制备及应用 | |
EA015510B1 (ru) | Способ увеличения количества мононуклеарных клеток у субъекта, страдающего раком, и используемая для этого фармацевтическая комбинация | |
CN105753978A (zh) | 一种hla-a11限制性癌胚抗原来源的表位肽及用途 | |
CN1948333B (zh) | 一种新的hPEBP4蛋白来源的HLA-A2限制性表位多肽及其应用 | |
CN106892974A (zh) | 一种基于肿瘤抗原ecm1的长肽ere1及其在肿瘤免疫治疗中的应用 | |
CN108289910A (zh) | 在体外人造淋巴结用于治疗和表位作图的t细胞的敏化和扩增 | |
JP2013047230A (ja) | Hla−a2陽性者用hsp105由来癌拒絶抗原ペプチド及びこれを含む医薬 | |
CN104761636A (zh) | 一种HLA-A33限制性eEF2表位多肽及其应用 | |
CN109371005A (zh) | 一种hla-0201限制性padi4表位多肽及其应用 | |
CN107050463A (zh) | 一种药物及其制备方法和应用 | |
JP6871432B2 (ja) | Plk1タンパク質に対する抗原に特異的なt細胞の免疫反応を誘導するhla−a2亜型に特異的なplk1由来の抗原決定基 | |
Himoudi et al. | Development of anti-PAX3 immune responses; a target for cancer immunotherapy | |
CN101812126B (zh) | 一种新的hPEBP4蛋白来源的HLA-A2限制性表位多肽及其应用 | |
CN104174015A (zh) | 疫苗组合物及其在肿瘤治疗中的用途 | |
JP5582542B2 (ja) | 腫瘍免疫誘導剤 | |
CN111057690A (zh) | 肿瘤相关基因braf突变相关抗原短肽及其应用 | |
Mansoor et al. | Genetically Modified T Cell Therapy Optimisation of the Chimeric T Cell Receptor for Cancer Therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Sun Weihong Inventor after: Sun Qingxiu Inventor after: Li Ying Inventor after: Niu Airong Inventor after: Wei Xiaofang Inventor after: Gao Daiqing Inventor before: Sun Weihong Inventor before: Wei Xiaofang Inventor before: Gao Daiqing |
|
CB03 | Change of inventor or designer information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180328 Address after: Qingdao City, Shandong province 266042 four Road No. 127 Applicant after: Zhongxin Hospital, Qingdao Address before: 266042 Shandong city of Qingdao province (city) four Road No. 127 biological treatment center Applicant before: Sun Weihong |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180427 Termination date: 20190414 |
|
CF01 | Termination of patent right due to non-payment of annual fee |